Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers
Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve highe...
Gespeichert in:
| Veröffentlicht in: | Annals of diagnostic pathology 2018-06, Vol.34, p.151-154 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154 |
|---|---|
| container_issue | |
| container_start_page | 151 |
| container_title | Annals of diagnostic pathology |
| container_volume | 34 |
| creator | Mauzo, Shakuntala H. Milton, Denái R. Prieto, Victor G. Torres-Cabala, Carlos A. Wang, Wei-Lien Chakravarti, Nitin Nagarajan, Priyadharsini Tetzlaff, Michael T. Curry, Jonathan L. Ivan, Doina Brown, Robert E. Aung, Phyu P. |
| description | Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity.
Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody.
SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients.
We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
•we confirmed the presence of SPARC expression in melanoma, KS, LMS and AS•we detected the presence of SPARC expression in AFX•ABI-007 could be beneficial in patients with AS, melanoma, LMS, AFX and KS |
| doi_str_mv | 10.1016/j.anndiagpath.2018.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2026423419</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1092913417303659</els_id><sourcerecordid>2026423419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-a2b44de01f8465c604a101df506c75639f309781c020f3f972431773c60973db3</originalsourceid><addsrcrecordid>eNqNkNtKAzEQhoMoWg-vIOudN7tODptsLkvxBAXF1uuQZrOauieT3aJvb0pVvBQCycA3mfk_hC4wZBgwv1pnum1Lp196PbxmBHCRAc0A8j00wTklaYFlsR_fIEkqMWVH6DiENQDGLBeH6IhIziHnYoKWi7FptP9MuiqxH723Ibiu3VaLx-nTLOl9N1jXJvGYcdCt7caQbHQwY619Esu-1qEJiW7LpHGNM2_Wh1N0UOk62LPv-wQ931wvZ3fp_OH2fjadp4YKMaSarBgrLeCqYDw3HJiO8coqB25EzqmsKEhRYAMEKlpJQRjFQtBISkHLFT1Bl7t_45bvow2Dalwwtq53eyoChDNCGZYRlTvU-C4EbyvVe7cNrjCorVS1Vn-kqq1UBVRFqbH3_HvMuGps-dv5YzECsx1gY9iNs14F42xrbOm8NYMqO_ePMV8Zio2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2026423419</pqid></control><display><type>article</type><title>Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers</title><source>Access via ScienceDirect (Elsevier)</source><creator>Mauzo, Shakuntala H. ; Milton, Denái R. ; Prieto, Victor G. ; Torres-Cabala, Carlos A. ; Wang, Wei-Lien ; Chakravarti, Nitin ; Nagarajan, Priyadharsini ; Tetzlaff, Michael T. ; Curry, Jonathan L. ; Ivan, Doina ; Brown, Robert E. ; Aung, Phyu P.</creator><creatorcontrib>Mauzo, Shakuntala H. ; Milton, Denái R. ; Prieto, Victor G. ; Torres-Cabala, Carlos A. ; Wang, Wei-Lien ; Chakravarti, Nitin ; Nagarajan, Priyadharsini ; Tetzlaff, Michael T. ; Curry, Jonathan L. ; Ivan, Doina ; Brown, Robert E. ; Aung, Phyu P.</creatorcontrib><description>Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity.
Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody.
SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients.
We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
•we confirmed the presence of SPARC expression in melanoma, KS, LMS and AS•we detected the presence of SPARC expression in AFX•ABI-007 could be beneficial in patients with AS, melanoma, LMS, AFX and KS</description><identifier>ISSN: 1092-9134</identifier><identifier>EISSN: 1532-8198</identifier><identifier>DOI: 10.1016/j.anndiagpath.2018.03.005</identifier><identifier>PMID: 29660567</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AFX ; Cutaneous angiosarcoma ; Immunohistochemical study ; Kaposi Sarcoma ; Melanoma ; SPARC expression</subject><ispartof>Annals of diagnostic pathology, 2018-06, Vol.34, p.151-154</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-a2b44de01f8465c604a101df506c75639f309781c020f3f972431773c60973db3</citedby><cites>FETCH-LOGICAL-c377t-a2b44de01f8465c604a101df506c75639f309781c020f3f972431773c60973db3</cites><orcidid>0000-0002-5346-2669</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.anndiagpath.2018.03.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29660567$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mauzo, Shakuntala H.</creatorcontrib><creatorcontrib>Milton, Denái R.</creatorcontrib><creatorcontrib>Prieto, Victor G.</creatorcontrib><creatorcontrib>Torres-Cabala, Carlos A.</creatorcontrib><creatorcontrib>Wang, Wei-Lien</creatorcontrib><creatorcontrib>Chakravarti, Nitin</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Tetzlaff, Michael T.</creatorcontrib><creatorcontrib>Curry, Jonathan L.</creatorcontrib><creatorcontrib>Ivan, Doina</creatorcontrib><creatorcontrib>Brown, Robert E.</creatorcontrib><creatorcontrib>Aung, Phyu P.</creatorcontrib><title>Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers</title><title>Annals of diagnostic pathology</title><addtitle>Ann Diagn Pathol</addtitle><description>Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity.
Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody.
SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients.
We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
•we confirmed the presence of SPARC expression in melanoma, KS, LMS and AS•we detected the presence of SPARC expression in AFX•ABI-007 could be beneficial in patients with AS, melanoma, LMS, AFX and KS</description><subject>AFX</subject><subject>Cutaneous angiosarcoma</subject><subject>Immunohistochemical study</subject><subject>Kaposi Sarcoma</subject><subject>Melanoma</subject><subject>SPARC expression</subject><issn>1092-9134</issn><issn>1532-8198</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkNtKAzEQhoMoWg-vIOudN7tODptsLkvxBAXF1uuQZrOauieT3aJvb0pVvBQCycA3mfk_hC4wZBgwv1pnum1Lp196PbxmBHCRAc0A8j00wTklaYFlsR_fIEkqMWVH6DiENQDGLBeH6IhIziHnYoKWi7FptP9MuiqxH723Ibiu3VaLx-nTLOl9N1jXJvGYcdCt7caQbHQwY619Esu-1qEJiW7LpHGNM2_Wh1N0UOk62LPv-wQ931wvZ3fp_OH2fjadp4YKMaSarBgrLeCqYDw3HJiO8coqB25EzqmsKEhRYAMEKlpJQRjFQtBISkHLFT1Bl7t_45bvow2Dalwwtq53eyoChDNCGZYRlTvU-C4EbyvVe7cNrjCorVS1Vn-kqq1UBVRFqbH3_HvMuGps-dv5YzECsx1gY9iNs14F42xrbOm8NYMqO_ePMV8Zio2Y</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Mauzo, Shakuntala H.</creator><creator>Milton, Denái R.</creator><creator>Prieto, Victor G.</creator><creator>Torres-Cabala, Carlos A.</creator><creator>Wang, Wei-Lien</creator><creator>Chakravarti, Nitin</creator><creator>Nagarajan, Priyadharsini</creator><creator>Tetzlaff, Michael T.</creator><creator>Curry, Jonathan L.</creator><creator>Ivan, Doina</creator><creator>Brown, Robert E.</creator><creator>Aung, Phyu P.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5346-2669</orcidid></search><sort><creationdate>20180601</creationdate><title>Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers</title><author>Mauzo, Shakuntala H. ; Milton, Denái R. ; Prieto, Victor G. ; Torres-Cabala, Carlos A. ; Wang, Wei-Lien ; Chakravarti, Nitin ; Nagarajan, Priyadharsini ; Tetzlaff, Michael T. ; Curry, Jonathan L. ; Ivan, Doina ; Brown, Robert E. ; Aung, Phyu P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-a2b44de01f8465c604a101df506c75639f309781c020f3f972431773c60973db3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AFX</topic><topic>Cutaneous angiosarcoma</topic><topic>Immunohistochemical study</topic><topic>Kaposi Sarcoma</topic><topic>Melanoma</topic><topic>SPARC expression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mauzo, Shakuntala H.</creatorcontrib><creatorcontrib>Milton, Denái R.</creatorcontrib><creatorcontrib>Prieto, Victor G.</creatorcontrib><creatorcontrib>Torres-Cabala, Carlos A.</creatorcontrib><creatorcontrib>Wang, Wei-Lien</creatorcontrib><creatorcontrib>Chakravarti, Nitin</creatorcontrib><creatorcontrib>Nagarajan, Priyadharsini</creatorcontrib><creatorcontrib>Tetzlaff, Michael T.</creatorcontrib><creatorcontrib>Curry, Jonathan L.</creatorcontrib><creatorcontrib>Ivan, Doina</creatorcontrib><creatorcontrib>Brown, Robert E.</creatorcontrib><creatorcontrib>Aung, Phyu P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of diagnostic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mauzo, Shakuntala H.</au><au>Milton, Denái R.</au><au>Prieto, Victor G.</au><au>Torres-Cabala, Carlos A.</au><au>Wang, Wei-Lien</au><au>Chakravarti, Nitin</au><au>Nagarajan, Priyadharsini</au><au>Tetzlaff, Michael T.</au><au>Curry, Jonathan L.</au><au>Ivan, Doina</au><au>Brown, Robert E.</au><au>Aung, Phyu P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers</atitle><jtitle>Annals of diagnostic pathology</jtitle><addtitle>Ann Diagn Pathol</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>34</volume><spage>151</spage><epage>154</epage><pages>151-154</pages><issn>1092-9134</issn><eissn>1532-8198</eissn><abstract>Serum protein acidic and rich in cysteine (SPARC) is a matricellular glycoprotein, which regulates cell proliferation and facilitates intracellular transport of albumin bound particles including chemotherapeutic agents such as Nab-paclitaxel/ABI-007. Therefore the presence of SPARC may achieve higher intra-tumoral drug concentration with lower dosage and thus reduce systemic side-effects. Several trials of ABI-007, in melanoma, show promising clinical activity.
Fifty-four cases of dermal based neoplasms were retrieved including 24 angiosarcomas (AS), 10 hemangiomas, 9 nodular melanomas, 4 Kaposi sarcomas (KS), 3 leiomyosarcomas (LMS), 3 atypical fibroxanthomas (AFX) and 1 spindle cell squamous cell carcinoma (SSCC). SPARC immunohistochemistry (IHC) was performed with a mouse monoclonal antibody.
SPARC expression was detected in a majority of AS (17/24), melanomas (8/9), AFX (3/3), LMS (3/3) and KS (4/4) with some expression in hemangiomas (3/10), while being negative in SSCC (0/1); and was significantly associated with tumor group (p = 0.017). Although a significant difference in overall survival was observed between SPARC expression groups (positive vs. negative) for all patients, there was no significant difference noted among angiosarcoma patients.
We have confirmed the presence of SPARC expression in melanoma, KS, LMS and AS and also detected it for the first time in AFX. Since paclitaxel has shown some effectiveness in AS, melanoma and KS, ABI-007 could also be beneficial in these patients.
•we confirmed the presence of SPARC expression in melanoma, KS, LMS and AS•we detected the presence of SPARC expression in AFX•ABI-007 could be beneficial in patients with AS, melanoma, LMS, AFX and KS</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29660567</pmid><doi>10.1016/j.anndiagpath.2018.03.005</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-5346-2669</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1092-9134 |
| ispartof | Annals of diagnostic pathology, 2018-06, Vol.34, p.151-154 |
| issn | 1092-9134 1532-8198 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2026423419 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | AFX Cutaneous angiosarcoma Immunohistochemical study Kaposi Sarcoma Melanoma SPARC expression |
| title | Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T10%3A15%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Summary%20of%20expression%20of%20SPARC%20protein%20in%20cutaneous%20vascular%20neoplasms%20and%20mimickers&rft.jtitle=Annals%20of%20diagnostic%20pathology&rft.au=Mauzo,%20Shakuntala%20H.&rft.date=2018-06-01&rft.volume=34&rft.spage=151&rft.epage=154&rft.pages=151-154&rft.issn=1092-9134&rft.eissn=1532-8198&rft_id=info:doi/10.1016/j.anndiagpath.2018.03.005&rft_dat=%3Cproquest_cross%3E2026423419%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2026423419&rft_id=info:pmid/29660567&rft_els_id=S1092913417303659&rfr_iscdi=true |